Department of Nephrology, Rouen University Hospital, Rouen, France.
Department of Adult Kidney Transplantation, Necker-Enfants Malades University Hospital, Paris, France.
Nephrol Dial Transplant. 2020 Feb 1;35(2):336-345. doi: 10.1093/ndt/gfz255.
Belatacept (bela) rescue therapy seems to be a valuable option for calcineurin inhibitor chronic toxicity in kidney transplantation. Nevertheless, the risk of infection associated with bela is not well reported.
We report the rate of opportunistic infections (OPI) after a switch to bela in a multicentric cohort of 280 kidney transplant patients.
Forty-two OPI occurred in 34 patients (12.1%), on average 10.8 ± 11.3 months after the switch. With a cumulative exposure of 5128 months of bela treatment, we found an incidence of 0.008 OPI/month of exposure, and 9.8 OPI/100 person-years. The most common OPI was cytomegalovirus (CMV) disease in 18/42 OPI (42.9%) and pneumocystis pneumonia in 12/42 OPI (28.6%). Two patients presented a progressive multifocal leucoencephalopathy and two patients developed a cerebral Epstein-Barr virus-induced post-transplant lymphoproliferative disease. OPI led to death in 9/34 patients (26.5%) and graft failure in 4/34 patients (11.8%). In multivariate analysis, estimated glomerular filtration rate <25/mL/min/1.73 m2 on the day of the switch and the use of immunosuppressive agents before transplantation were associated with the occurrence of OPI. We found a higher rate of infection-related hospitalization (24.1 versus 12.3/100 person-years, P = 0.0007) and also a higher rate of OPI (13.2 versus 6.7/100 person-years, P = 0.005) in the early conversion group (within 6 months).
The risk of OPI is significant post-conversion to bela and may require additional monitoring and prophylactic therapy, particularly regarding pneumocystis pneumonia and CMV disease. These data need to be confirmed in a larger case-control study.
贝他西普(bela)解救疗法似乎是治疗肾移植中环孢素慢性毒性的一种有价值的选择。然而,与 bela 相关的感染风险并未得到很好的报道。
我们报告了在 280 例肾移植患者的多中心队列中,转换为 bela 后机会性感染(OPI)的发生率。
34 例患者(12.1%)共发生 42 例 OPI,平均在转换后 10.8±11.3 个月。累计暴露于 bela 治疗 5128 个月后,我们发现 OPI 发生率为 0.008/月,100 人年中有 9.8 例 OPI。最常见的 OPI 是 18/42 例(42.9%)巨细胞病毒(CMV)疾病和 12/42 例(28.6%)肺孢子菌肺炎。2 例患者出现进行性多灶性白质脑病,2 例患者发生脑 Epstein-Barr 病毒诱导的移植后淋巴组织增生性疾病。OPI 导致 9/34 例患者(26.5%)死亡和 4/34 例患者(11.8%)移植物失功。多变量分析显示,转换日肾小球滤过率<25/mL/min/1.73m2 和移植前使用免疫抑制剂与 OPI 的发生相关。我们发现感染相关住院率较高(24.1 比 12.3/100 人年,P=0.0007),早期转换组(6 个月内) OPI 发生率也较高(13.2 比 6.7/100 人年,P=0.005)。
转换为 bela 后 OPI 的风险显著增加,可能需要额外的监测和预防治疗,特别是针对肺孢子菌肺炎和 CMV 疾病。这些数据需要在更大的病例对照研究中得到证实。